Abstract
Although first-generation drug-eluting stents (DES) have significantly reduced the risk of in-stent restenosis, they have also increased the long-term risk of stent thrombosis. This safety concern directly triggered the development of new generation DES, with innovations in stent platforms, polymers, and anti-proliferative drugs. Stent platform materials have evolved from stainless steel to cobalt or platinum-chromium alloys with an improved strut design. Drug-carrying polymers have become biocompatible or biodegradable and even polymer-free DES were introduced. New limus-family drugs (such as everolimus, zotarolimus or biolimus) were adopted to enhance stent performances. As a result, these new DES demonstrated superior vascular healing responses on intracoronary imaging studies and lower stent thrombotic events in actual patients. Recently, fully-bioresorbable stents (scaffolds) have been introduced, and expanding their applications. In this article, the important concepts and clinical results of new generation DES and bioresorbable scaffolds are described.
| Original language | English |
|---|---|
| Pages (from-to) | 87-104 |
| Number of pages | 18 |
| Journal | Expert Review of Cardiovascular Therapy |
| Volume | 14 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2016 Jan 2 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Cardiology and Cardiovascular Medicine
Cite this
}
Drug-eluting stents to prevent stent thrombosis and restenosis. / Im, Eui; Hong, Myeongki.
In: Expert Review of Cardiovascular Therapy, Vol. 14, No. 1, 02.01.2016, p. 87-104.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Drug-eluting stents to prevent stent thrombosis and restenosis
AU - Im, Eui
AU - Hong, Myeongki
PY - 2016/1/2
Y1 - 2016/1/2
N2 - Although first-generation drug-eluting stents (DES) have significantly reduced the risk of in-stent restenosis, they have also increased the long-term risk of stent thrombosis. This safety concern directly triggered the development of new generation DES, with innovations in stent platforms, polymers, and anti-proliferative drugs. Stent platform materials have evolved from stainless steel to cobalt or platinum-chromium alloys with an improved strut design. Drug-carrying polymers have become biocompatible or biodegradable and even polymer-free DES were introduced. New limus-family drugs (such as everolimus, zotarolimus or biolimus) were adopted to enhance stent performances. As a result, these new DES demonstrated superior vascular healing responses on intracoronary imaging studies and lower stent thrombotic events in actual patients. Recently, fully-bioresorbable stents (scaffolds) have been introduced, and expanding their applications. In this article, the important concepts and clinical results of new generation DES and bioresorbable scaffolds are described.
AB - Although first-generation drug-eluting stents (DES) have significantly reduced the risk of in-stent restenosis, they have also increased the long-term risk of stent thrombosis. This safety concern directly triggered the development of new generation DES, with innovations in stent platforms, polymers, and anti-proliferative drugs. Stent platform materials have evolved from stainless steel to cobalt or platinum-chromium alloys with an improved strut design. Drug-carrying polymers have become biocompatible or biodegradable and even polymer-free DES were introduced. New limus-family drugs (such as everolimus, zotarolimus or biolimus) were adopted to enhance stent performances. As a result, these new DES demonstrated superior vascular healing responses on intracoronary imaging studies and lower stent thrombotic events in actual patients. Recently, fully-bioresorbable stents (scaffolds) have been introduced, and expanding their applications. In this article, the important concepts and clinical results of new generation DES and bioresorbable scaffolds are described.
UR - http://www.scopus.com/inward/record.url?scp=84949730851&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949730851&partnerID=8YFLogxK
U2 - 10.1586/14779072.2016.1112267
DO - 10.1586/14779072.2016.1112267
M3 - Review article
C2 - 26567863
AN - SCOPUS:84949730851
VL - 14
SP - 87
EP - 104
JO - Expert Review of Cardiovascular Therapy
JF - Expert Review of Cardiovascular Therapy
SN - 1477-9072
IS - 1
ER -